High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$2.7M
$2,708,535
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
ELVN
M
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
Other
2026-03-10
$25,120
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2026-03-10 | $25,120 | M | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -28.8%
2026-03-10
$305,827
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -28.8%
|
2026-03-10 | $305,827 | S | Form 4 |
|
ELVN
M
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
Other
2026-03-09
$74,080
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2026-03-09 | $74,080 | M | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -54.4%
2026-03-09
$896,811
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -54.4%
|
2026-03-09 | $896,811 | S | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Hohl Benjamin
• CFO
Discretionary SellΔOwn -16.4%
2026-03-06
$295,839
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
CFO
Discretionary SellΔOwn -16.4%
|
2026-03-06 | $295,839 | S | Form 4 |
|
ELVN
M
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
Other
2026-02-17
$111,600
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
Other
|
2026-02-17 | $111,600 | M | Form 4 |
|
ELVN
S
Enliven Therapeutics, Inc.
Collins Helen Louise
• Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -64.3%
2026-02-17
$1,177,862Large
|
||||||
| ELVN |
Enliven Therapeutics, Inc.
|
Officer • CHIEF MEDICAL OFFICER
10b5-1 SellΔOwn -64.3%
|
2026-02-17 | $1,177,862Large | S | Form 4 |
| ELVN |
Enliven Therapeutics, Inc.
|
Director
10b5-1 Sell
|
2026-02-17 | $32,196 | S | Form 4 |